Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.29 USD | -3.23% | -0.96% | -17.35% |
May. 13 | Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours | MT |
May. 13 | Transcript : Theravance Biopharma, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Business Summary
Number of employees: 99
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Human Therapeutics
100.0
%
| 51 | 100.0 % | 57 | 100.0 % | +11.84% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
99.6
%
| 51 | 99.6 % | 57 | 99.6 % | +11.89% |
Europe
0.4
%
| 0 | 0.4 % | 0 | 0.4 % | +0.45% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Rick Winningham
CEO | Chief Executive Officer | 64 | 13-06-30 |
Aziz Sawaf
DFI | Director of Finance/CFO | 42 | 14-05-31 |
Stuart Knight
CTO | Chief Tech/Sci/R&D Officer | - | 14-10-31 |
Richard Graham
CTO | Chief Tech/Sci/R&D Officer | - | - |
Rhonda Farnum
CTO | Chief Tech/Sci/R&D Officer | 59 | 18-06-30 |
Aine Miller
PRN | Corporate Officer/Principal | 47 | - |
Stacy Pryce
PRN | Corporate Officer/Principal | - | - |
Brett Grimaud
LAW | General Counsel | 50 | 21-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Dean Mitchell
BRD | Director/Board Member | 68 | 14-05-31 |
Eran Broshy
BRD | Director/Board Member | 65 | 14-06-01 |
Director/Board Member | 59 | 20-06-30 | |
Susannah Gray
BRD | Director/Board Member | 63 | 23-02-25 |
Rick Winningham
CEO | Chief Executive Officer | 64 | 13-06-30 |
Jim Kelly
BRD | Director/Board Member | 43 | 23-04-10 |
Donal O'Connor
BRD | Director/Board Member | 73 | 15-10-20 |
Laurie Alsup
BRD | Director/Board Member | 70 | 18-02-12 |
Jeremy Grant
BRD | Director/Board Member | 36 | Dec. 20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 48,633,224 | 41,511,649 ( 85.36 %) | 0 | 85.36 % |
Company contact information
Theravance Biopharma, Inc.
901 Gateway Boulevard
94080, South San
+650 808 6000
http://www.theravance.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.35% | 452M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- TBPH Stock
- Company Theravance Biopharma, Inc.